// App-Quantinova.ai

ES20.02 : Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer

Researchers

Presenter

  • S. Popat

Principal Investigators

  • N/A

Medical Centers

  • The Royal Marsden Hospital and the Institute of Cancer Research, London/GB

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Multiple Myeloma

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Cancer antigen 15-3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved